<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50249">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452047</url>
  </required_header>
  <id_info>
    <org_study_id>7655A-013</org_study_id>
    <secondary_id>2015-000066-62</secondary_id>
    <secondary_id>163367</secondary_id>
    <nct_id>NCT02452047</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)</brief_title>
  <acronym>RESTORE-IMI 1</acronym>
  <official_title>A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Estimate the Efficacy and Safety of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem/Cilastatin in Subjects With Imipenem-Resistant Bacterial Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (MK-7655A)
      versus colistimethate sodium + imipenem+cilastatin in the treatment of imipenem-resistant
      bacterial infections. Infections evaluated in the study will be hospital-acquired bacterial
      pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), complicated
      intra-abdominal infection (cIAI), and complicated urinary tract infection (cUTI).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with a Favorable Overall Response</measure>
    <time_frame>Up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with One or More Tier 1 Adverse Event</measure>
    <time_frame>Up to Day 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with One or More Tier 2 Adverse Event</measure>
    <time_frame>Up to Day 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with One or More Tier 3 Adverse Event</measure>
    <time_frame>Up to Day 35</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Clinical Response</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with All-cause Mortality</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Treatment-emergent Nephrotoxicity</measure>
    <time_frame>Day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Clinical Response</measure>
    <time_frame>Day 3 (On Therapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Clinical Response</measure>
    <time_frame>Up to Day 21 (End of Therapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Clinical Response</measure>
    <time_frame>Up to Day 30 (5 to 9 Days after End of Therapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Microbiological Response</measure>
    <time_frame>Day 3 (On Therapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Microbiological Response</measure>
    <time_frame>Up to Day 21 (End of Therapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Favorable Microbiological Response</measure>
    <time_frame>Up to Day 30 (5 to 9 Days after End of Therapy)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Group 1: Imipenem+Cilastatin/Relebactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours and placebo for colistimethate sodium IV infusion once every 12 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Colistimethate sodium + Imipenem+Cilastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive colistimethate sodium IV infusion once every 12 hours and imipenem+cilastatin IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Imipenem+Cilastatin/Relebactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with documented imipenem-resistant and colistin-resistant bacterial infections may be eligible to receive open-label imipenem+cilastatin/relebactam IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem+Cilastatin/Relebactam</intervention_name>
    <description>Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours</description>
    <arm_group_label>Group 1: Imipenem+Cilastatin/Relebactam</arm_group_label>
    <arm_group_label>Group 3: Imipenem+Cilastatin/Relebactam</arm_group_label>
    <other_name>MK-7655A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistimethate sodium (CMS)</intervention_name>
    <description>Colistimethate base activity 300 mg (~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (~180 to 360 mg CMS), depending on renal function, once every 12 hours</description>
    <arm_group_label>Group 2: Colistimethate sodium + Imipenem+Cilastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem+Cilastatin</intervention_name>
    <description>Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours</description>
    <arm_group_label>Group 2: Colistimethate sodium + Imipenem+Cilastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to CMS</intervention_name>
    <description>Placebo to CMS IV infusion once every 12 hours</description>
    <arm_group_label>Group 1: Imipenem+Cilastatin/Relebactam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalization that requires treatment with IV antibiotic therapy for a new,
             persistent or progressing bacterial infection involving at least 1 of 3 primary
             infection types (HABP, VABP, cIAI, or cUTI)

          -  Positive culture data from the primary infection-site specimen collected within 1
             week of study entry. At least one of the suspected causative pathogens from the
             specimen meets all of the following: 1) identified as a Gram-negative bacterium, 2)
             culture-confirmed imipenem resistance (and colistin resistance for Group 3 only), 3)
             culture-confirmed susceptibility to imipenem/relebactam and to colistin (for Groups 1
             and 2 only)

          -  Not of reproductive potential, or of reproductive potential and agrees to avoid
             becoming pregnant or impregnating a partner by complying with one of the following:
             1) practice abstinence, or 2) use of acceptable contraception during heterosexual
             activity

        Exclusion Criteria:

          -  Concurrent infection that would interfere with evaluation of the response to the
             study antibiotics

          -  Received treatment with any form of systemic colistin for &gt;24 hours within 72 hours
             before initiation of study drug (for Groups 1 and 2 only)

          -  HABP or VABP caused by an obstructive process

          -  cUTI which meets any of the following: 1) complete obstruction of any portion of the
             urinary tract, 2) known ileal loop, 3) intractable vesico-ureteral reflux, 4)
             presence of an indwelling urinary catheter which cannot be removed at study entry

          -  History of serious allergy, hypersensitivity, or any serious reaction to listed
             antibiotics (per-protocol)

          -  Female who is pregnant or is expecting to conceive (or a male partner of a female who
             is expecting to conceive), is breastfeeding, or plans to breastfeed before completion
             of the study

          -  Anticipated treatment with any of the following during the study: valproic acid or
             divalproex sodium, or concomitant systemic (e.g. IV, oral or inhaled) antimicrobial
             agents with known Gram-negative bacterial coverage

          -  Currently undergoing hemodialysis or peritoneal dialysis

          -  Participated or anticipates participating in any other clinical study involving
             administration of investigational medication up to 30 days before screening or during
             the course of the trial

          -  Concurrent endocarditis, osteomyelitis, meningitis, prosthetic joint infection,
             disseminated fungal infection, or active pulmonary tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 1320)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 1319)</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MSD Brasil</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MSD Online</last_name>
      <phone>0800 012 22 32</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MDS Colombia SAS</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Carvajal</last_name>
      <phone>57 1219109011090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme OU</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>+46 (0) 8ý578ý135 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Sharp &amp; Dohme GmbH</name>
      <address>
        <city>Haar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Medical Information Center</last_name>
      <phone>49 800 673 673 673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vianex, S.A. / MSD</name>
      <address>
        <city>Alimos</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lazaros Poughias</last_name>
      <phone>30 2109897322</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Italia S.r.l.</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Nardini</last_name>
      <phone>39 06 361911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD K.K.</name>
      <address>
        <city>Chiyoda-Ku, Tokyo</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Japan Call Center</last_name>
      <phone>81-3-6272-1957</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Korea LTD</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jongho Ahn</last_name>
      <phone>82-2-331-2000 2015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Latvija SIA</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>+46 (0) 8ý578ý135 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UAB &quot;Merck Sharp &amp; Dohme&quot;</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>+46 (0) 8ý578ý135 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Marques</last_name>
      <phone>52 55254819608</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme, Peru S.R.L.</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Espinoza</last_name>
      <phone>(51-1) 411-5100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Romania SRL</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Olaru</last_name>
      <phone>38 (044) 393 74 80</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD (Pty) LTD South Africa</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khanyi Mzolo</last_name>
      <phone>27 11 655 3140</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ilaclari Ltd. Sti</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alev Eren</last_name>
      <phone>90 212 336 12 63</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Ukraine LLC</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eran Gefen</last_name>
      <phone>38 (044) 393 74 80</phone>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 8, 2017</lastchanged_date>
  <firstreceived_date>May 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>MK-7655</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Colistin</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
